

tamsulosin (Flomaxtra XL)

(No. 149/04)

Yamanouchi Pharma Ltd

Product Update

10 December 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

Tamsulosin hydrochloride film-coated extended release tablets 400 microgram (equivalent to 367 microgram tamsulosin) are accepted for use in NHS Scotland for functional symptoms of benign prostatic hypertrophy as an alternative to modified release capsules.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 26 October 2004.

**Chairman
Scottish Medicines Consortium**